Merus BV (MRUS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Sven A. Lundberg
Employees:
37
YALELAAN 62, 3584 CM UTRECHT, NETHERLANDS 3584 CM
31 030 253 8800

Merus N.V. engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials. The company is also developing MCLA-158,158,145, and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.

Data derived from most recent annual or quarterly report
Market Cap 690.897 Million Shares Outstanding43.48 Million Avg 30-day Volume 473.892 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.64
Price to Revenue12.0008 Debt to Equity0.0 EBITDA-31.59 Million
Price to Book Value3.0248 Operating Margin-125.8063 Enterprise Value591.118 Million
Current Ratio6.618 EPS Growth0.517 Quick Ratio6.306
1 Yr BETA 1.0646 52-week High/Low 33.09 / 12.03 Profit Margin-65.4523
Operating Cash Flow Growth-224.0149 Altman Z-Score4.3155 Free Cash Flow to Firm -68.416 Million
View SEC Filings from MRUS instead.

View recent insider trading info

Funds Holding MRUS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MRUS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-05-31:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-01-25:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-08:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-05-28:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-01-22:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-01-20:
    Item 1.02: Termination of a Material Definitive Agreement
  • 8-K: filed on 2021-01-19:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.02: Results of Operations and Financial Condition
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
  • 8-K: filed on 2020-09-02:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-07:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-07-06:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    14.7 Thousand total shares from 1 transactions

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    LUNDBERG SVEN ANTE PRESIDENT, CEO & PFO

    • Officer
    • Director
    78,071 2022-11-03 6

    SHUMAN HARRY VP CONTROLLER, PAO

    • Officer
    1,760 2022-08-25 3

    PERRY GREGORY D

    • Director
    16,604 2022-05-31 1

    GOWEN MAXINE

    • Director
    16,604 2022-05-31 1

    IWICKI MARK T

    • Director
    16,604 2022-05-31 1

    PUCCI PAOLO

    • Director
    16,604 2022-05-31 1

    MEHRA ANAND

    • Director
    16,604 2022-05-31 1

    SANDOR VICTOR

    • Director
    16,604 2022-05-31 1

    KANAVY LEN

    • Director
    16,604 2022-05-31 1

    SILVERMAN PETER B. EVP, GC AND HEAD OF UTRECHT

    • Officer
    21,100 2022-03-10 2

    BAKKER LEX SVP, CHIEF DEVELOPMENT OFFICER

    • Officer
    55,000 2022-01-31 1

    DE KRUIF JOHN SVP & CHIEF TECHNOLOGY OFFICER

    • Officer
    55,000 2022-01-31 1

    LIU HUI EVP, CBO & HEAD OF MERUS US

    • Officer
    83,000 2022-01-31 1

    JOE ANDREW SVP, CMO

    • Officer
    83,000 2022-01-31 1

    GEUIJEN CECILE A W SVP & CHIEF SCIENTIFIC OFFICER

    • Officer
    55,000 2022-01-31 1

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BVF I GP LLC

    BIOTECHNOLOGY VALUE FUND II LP

    BVF II GP LLC

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF GP HOLDINGS LLC

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    7,824,899 2021-10-07 0

    INCYTE CORP

    • 10% Owner
    No longer subject to file 2021-01-25 0

    THROSBY MARK EVP & CHIEF SCIENTIFIC OFFICER

    • Officer
    45,515 2020-07-07 0

    BVF GP HOLDINGS LLC

    BVF I GP LLC

    BVF II GP LLC

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    3,190,994 2020-06-01 0

    SIRULNIK ANDRES EVP & CHIEF MEDICAL OFFICER

    • Officer
    0 2020-02-14 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    3,435,297 2020-01-16 0

    DE KONING JOHN

    • Director
    0 2020-01-01 0

    GREIG RUSSELL

    • Director
    0 2020-01-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    LUNDBERG SVEN ANTE - Director - Officer PRESIDENT, CEO & PFO

    2022-11-03 14:07:58 -0400 2022-11-03 P 14,706 $14.38 a 40,576 direct yes 11.7147 22.7749 22.7749 6 0.0 1

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    MERUS NV MRUS 2022-11-25 22:15:03 UTC 3.2234 0.5966 10000
    MERUS NV MRUS 2022-11-25 21:45:04 UTC 3.2234 0.5966 10000
    MERUS NV MRUS 2022-11-25 21:15:03 UTC 3.2234 0.5966 10000
    MERUS NV MRUS 2022-11-25 20:45:03 UTC 3.2234 0.5966 10000
    MERUS NV MRUS 2022-11-25 20:15:03 UTC 3.2234 0.5966 10000
    MERUS NV MRUS 2022-11-25 19:45:04 UTC 3.2234 0.5966 10000
    MERUS NV MRUS 2022-11-25 19:15:03 UTC 3.2234 0.5966 10000
    MERUS NV MRUS 2022-11-25 18:45:03 UTC 3.2234 0.5966 10000
    MERUS NV MRUS 2022-11-25 18:15:03 UTC 3.2234 0.5966 10000
    MERUS NV MRUS 2022-11-25 17:45:04 UTC 3.2234 0.5966 10000
    MERUS NV MRUS 2022-11-25 17:15:03 UTC 3.2234 0.5966 10000
    MERUS NV MRUS 2022-11-25 16:45:04 UTC 3.2189 0.6011 10000
    MERUS NV MRUS 2022-11-25 16:15:03 UTC 3.2189 0.6011 10000
    MERUS NV MRUS 2022-11-25 15:45:03 UTC 3.2189 0.6011 10000
    MERUS NV MRUS 2022-11-25 15:15:03 UTC 3.2189 0.6011 10000
    MERUS NV MRUS 2022-11-25 14:45:04 UTC 3.2189 0.6011 7000
    MERUS NV MRUS 2022-11-25 14:15:04 UTC 3.2189 0.6011 10000
    MERUS NV MRUS 2022-11-25 13:45:03 UTC 2.8817 0.9383 10000
    MERUS NV MRUS 2022-11-25 13:15:03 UTC 2.8817 0.9383 10000
    MERUS NV MRUS 2022-11-25 12:45:03 UTC 2.8817 0.9383 10000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments